Skip to main content

Neonatal Encephalopathy clinical trials at University of California Health

2 in progress, 0 open to eligible people

Showing trials for
  • High-dose Erythropoietin or placebo for birth asphyxia and neonatal encephalopathy

    “Study looking at High-dose Erythropoietin with standard care or placebo with standard of care has better outcomes for infants with HIE”

    Sorry, in progress, not accepting new patients

    Hypoxic-ischemic encephalopathy (HIE) occurs when a baby gets reduced blood flow and oxygen to the brain near the time of birth. This results in death or neurologic disabilities including cerebral palsy and cognitive impairment in up to half of affected infants. This clinical trial will determine if the drug erythropoietin (Epo) added to hypothermia (usual therapy) will improve outcomes for infants suffering from HIE.

    at UCSF

  • TIME Study: Therapeutic Hypothermia for Infants With Mild Encephalopathy

    Sorry, not yet accepting patients

    The TIME study is a randomized, controlled trial to evaluate impact on early measures of neurodevelopment and the safety profile of therapeutic hypothermia in term neonates with Mild Hypoxic-Ischemic Encephalopathy who are < 6 hours of age. Neurodevelopmental outcome will be assessed at 12-14 months of age. The study will enroll 68 neonates randomized to therapeutic hypothermia or normothermia across 5 centers in California.

    at UCSF

Last updated: